Arena Pharmaceuticals’ Lorcaserin For Obesity Passes Major Safety Milestone
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that following a planned review by an independent Echocardiographic Data Safety Monitoring Board (EDSMB) it is continuing BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), a pivotal trial evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity.
More: continued here
Filed under: Obesity / Weight Loss / Fitness on April 2nd, 2008